643 related articles for article (PubMed ID: 12813409)
1. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
Zhang X; Chaudhry A; Chintala SK
Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of plasminogen activators attenuates the death of differentiated retinal ganglion cells and stabilizes their neurite network in vitro.
Harvey R; Chintala SK
Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1884-91. PubMed ID: 17389524
[TBL] [Abstract][Full Text] [Related]
3. Tissue and urokinase plasminogen activators instigate the degeneration of retinal ganglion cells in a mouse model of glaucoma.
Chintala SK
Exp Eye Res; 2016 Feb; 143():17-27. PubMed ID: 26474495
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activators promote excitotoxicity-induced retinal damage.
Mali RS; Cheng M; Chintala SK
FASEB J; 2005 Aug; 19(10):1280-9. PubMed ID: 16051695
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
6. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.
Baricos WH; Cortez SL; el-Dahr SS; Schnaper HW
Kidney Int; 1995 Apr; 47(4):1039-47. PubMed ID: 7540230
[TBL] [Abstract][Full Text] [Related]
7. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
Turner PC; Baquero MT; Yuan S; Thoennes SR; Moyer RW
Virology; 2000 Jul; 272(2):267-80. PubMed ID: 10873770
[TBL] [Abstract][Full Text] [Related]
8. Tissue type plasminogen activator facilitates NMDA-receptor-mediated retinal apoptosis through an independent fibrinolytic cascade.
Kumada M; Niwa M; Hara A; Matsuno H; Mori H; Ueshima S; Matsuo O; Yamamoto T; Kozawa O
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1504-7. PubMed ID: 15790922
[TBL] [Abstract][Full Text] [Related]
9. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Meissauer A; Kramer MD; Schirrmacher V; Brunner G
Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.
Lund LR; Green KA; Stoop AA; Ploug M; Almholt K; Lilla J; Nielsen BS; Christensen IJ; Craik CS; Werb Z; Danø K; Rømer J
EMBO J; 2006 Jun; 25(12):2686-97. PubMed ID: 16763560
[TBL] [Abstract][Full Text] [Related]
11. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
12. Melatonin inhibits postischemic matrix metalloproteinase-9 (MMP-9) activation via dual modulation of plasminogen/plasmin system and endogenous MMP inhibitor in mice subjected to transient focal cerebral ischemia.
Tai SH; Chen HY; Lee EJ; Chen TY; Lin HW; Hung YC; Huang SY; Chen YH; Lee WT; Wu TS
J Pineal Res; 2010 Nov; 49(4):332-41. PubMed ID: 20663046
[TBL] [Abstract][Full Text] [Related]
13. Maspin increases extracellular plasminogen activator activity associated with corneal fibroblasts and myofibroblasts.
Warejcka DJ; Narayan M; Twining SS
Exp Eye Res; 2011 Nov; 93(5):618-27. PubMed ID: 21810423
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of reactive gliosis attenuates excitotoxicity-mediated death of retinal ganglion cells.
Ganesh BS; Chintala SK
PLoS One; 2011 Mar; 6(3):e18305. PubMed ID: 21483783
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling.
Stewart AG; Xia YC; Harris T; Royce S; Hamilton JA; Schuliga M
Br J Pharmacol; 2013 Dec; 170(7):1421-35. PubMed ID: 24111848
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid-mediated neuroprotection in retinal ischemia injury via histone deacetylase inhibition and transcriptional activation.
Zhang Z; Qin X; Tong N; Zhao X; Gong Y; Shi Y; Wu X
Exp Eye Res; 2012 Jan; 94(1):98-108. PubMed ID: 22143029
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Ramont L; Pasco S; Hornebeck W; Maquart FX; Monboisse JC
Exp Cell Res; 2003 Nov; 291(1):1-10. PubMed ID: 14597403
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
20. Amiloride selectively inhibits the urokinase-type plasminogen activator.
Vassalli JD; Belin D
FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
